Evidence map›Paper›PMID 35064226›Full record

ArticleCell research2022

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates.

Denisa Bojkova, Marek Widera, Sandra Ciesek, Mark N Wass, Martin Michaelis, Jindrich Cinatl

Open access · bronzeAbstract readLetter
In one paragraph

Article in Cell research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Extracellular vesicles in viral disease management.Current research in microbial sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. COVID-19 therapeutics.Clinical microbiology reviews · 2024
    Review
  12. Update on Omicron variant and its threat to vulnerable populations.Public health in practice (Oxford, England) · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Denisa BojkovaInstitute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany.
Marek WideraInstitute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0001-5417-9307
Sandra CiesekInstitute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany.
Mark N WassSchool of Biosciences, University of Kent, Canterbury, UK. M.N.Wass@kent.ac.uk.
Martin MichaelisSchool of Biosciences, University of Kent, Canterbury, UK. M.Michaelis@kent.ac.uk.ORCID http://orcid.org/0000-0002-5710-5888
Jindrich CinatlInstitute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany. Cinatl@em.uni-frankfurt.de.ORCID http://orcid.org/0000-0002-6744-2087
Goethe University Frankfurt · DEUniversity of Kent · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsHumansInterferonsAntiviral AgentsInterferons

Identifiers

PMID35064226
PMCPMC8781709
OpenAlexW4206023359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.